Adipose-derived stem cell conditioned medium impacts asymptomatic peripheral neuromuscular denervation in the mutant superoxide dismutase (G93A) transgenic mouse model of amyotrophic lateral sclerosis

Abstract

Background:

Amyotrophic lateral sclerosis (ALS) is devastating, leading to paralysis and death. Disease onset begins pre-symptomatically through spinal motor neuron (MN) axon die-back from musculature at ∼47 days of age in the mutant superoxide dismutase 1 (mSOD1^G93A) transgenic ALS mouse model. This period may be optimal to assess potential therapies. We previously demonstrated that post-symptomatic adipose-derived stem cell conditioned medium (ASC-CM) treatment is neuroprotective in mSOD1^G93A mice. We hypothesized that early disease onset treatment could ameliorate neuromuscular junction (NMJ) disruption.

Objective:

To determine whether pre-symptom administration of ASC-CM prevents early NMJ disconnection.

Methods:

We confirmed the NMJ denervation time course in mSOD1^G93A mice using co-labeling of neurofilament and post-synaptic acetylcholine receptors (AchR) by α-bungarotoxin. We determined whether ASC-CM ameliorates early NMJ loss in mSOD1^G93A mice by systemically administering 200μl ASC-CM or vehicle medium daily from post-natal days 35 to 47 and quantifying intact NMJs through co-labeling of neurofilament and synaptophysin with α-bungarotoxin in gastrocnemius muscle.

Results:

Intact NMJs were significantly decreased in 47 day old mSOD1^G93A mice (p < 0.05), and daily systemic ASC-CM prevented disease-induced NMJ denervation compared to vehicle treated mice (p < 0.05).

Conclusions:

Our results lay the foundation for testing the long-term neurological benefits of systemic ASC-CM therapy in the mSOD1^G93A mouse model of ALS.